Epigenomics AG - Company Profile
Powered by 
All the sales intelligence you need on Epigenomics AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Epigenomics AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Epigenomics AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Epigenomics AG’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 12 Jun 2023 | Epigenomics Sells Assets to New Day Diagnostics for USD1.8 Million | Asset Transaction |
New Day Diagnostics LLC
|
Epigenomics AG |
| 14 Dec 2022 | Epigenomics Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center | Partnership | - |
Epigenomics Inc
University of Texas MD Anderson Cancer Center
|
| 27 Apr 2021 | Epigenomics Raises USD2.6 Million in Rights Offering of Shares | Equity Offering | - |
Epigenomics AG |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer